Shares of Lonza Group AG (OTCMKTS:LZAGY – Get Rating) have earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $842.50.
Several brokerages have issued reports on LZAGY. Morgan Stanley dropped their target price on shares of Lonza Group from CHF 800 to CHF 785 and set an “equal weight” rating on the stock in a report on Monday, April 4th. Royal Bank of Canada upgraded shares of Lonza Group from a “sector perform” rating to an “outperform” rating in a report on Friday, May 20th.
Shares of Lonza Group stock opened at $50.94 on Thursday. Lonza Group has a 1 year low of $49.70 and a 1 year high of $86.31. The firm’s 50-day moving average is $57.50 and its two-hundred day moving average is $67.09.
Lonza Group Company Profile (Get Rating)
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals.
- Get a free copy of the StockNews.com research report on Lonza Group (LZAGY)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.